We provide experience-based consulting services for Biotech, Pharma and Medtech clients globally. Technical consulting, project management, strategy and management consulting, market and opportunity analyses are some of our core areas of expertise.go
Ventac Partners has a global network of Life Science investors in Europe, US and Asia as well as expertise in founding and growing companies on behalf of clients. Unlike other consulting agencies, we also found, actively manage, grow and help exit innovative Portfolio Companies co-owned with partners & investors.go
We offer extensive buy and sell-side transaction experience with a truly international reach in virtually all Life Science sectors. Our specialties include in- and out-licensing, mergers & acquisitions, business development and marketing collaborations in all continents.go
APIM Therapeutics, a Ventac Partners portfolio company, has announced that the company has closed a Financing round raising 25 mNOK ($3M). Funds will be used to file a Clinical Trial Application (CTA) and start the clinical development program of APIM Therapeutics’ anti-cancer lead compound, ATX-101. A copy of the relevant press release is available here.
RhoVac, a Ventac Partners portfolio company, announced that the first patient in the company’s clinical phase I/II study has now completed the treatment phase with cancer vaccine RV001. For more information, please visit this link.
Ventac Partners Mikael Oerum and Scott Woodward will be attending BioPharm America in Boston, USA.
Ventac Partners Mikael Oerum and Scott Woodward will be attending the BIO Annual Meeting in San Diego, USA.
Ventac portfolio companies, APIM Therapeutics and Avexxin, will be participating at BioEurope Spring Partnering meeting, in Barcelona, Spain (March 20-22, 2017).